Mode
Text Size
Log in / Sign up
Phase 3 N=497

Naproxen Sodium Extended-Release Actual Use Study

Pain

Enrolled (actual)
497
Serious AEs
0.6%
Results posted
May 2011
Primary outcome: Primary: Use Days With One or More Misuse Occasions — 2112; 294 days

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Naproxen Sodium ER (BAYH6689) (Drug)
Age
Pediatric, Adult, Older Adult · 12+ yrs
Sex
All
Sponsor
Bayer
Primary completion
Nov 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Use Days With One or More Misuse Occasions
2112; 294
SECONDARY
Dosing Occasions With One and More Than One Tablet Taken
2500; 66
SECONDARY
Use Days With and Without Next Dose Less Than 22 Hours Later
2175; 231
SECONDARY
Number of Subjects With and Without More Than One Tablet Taken Per Dose
440; 27
SECONDARY
Number of Subjects With and Without Next Dose Less Than 22 Hours Later
359; 108
SECONDARY
Number of Subjects With and Without More Than 660 mg at Least Once
344; 123
SECONDARY
Average Daily Dose
722
SECONDARY
Number of Subjects That Have Taken Study Drug on More Than 10 Consecutive Days and Not on More Than 10 Consecutive Days
376; 109
SECONDARY
Number of Total Dosing Occasions Per Subject
5.5
SECONDARY
Number of Dosing Occasions Per Subject That Exceeded 660 mg
0.6

Summary

The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.

Eligibility Criteria

Inclusion Criteria

  • Self report use of Over The Counter (OTC) analgesics
  • Able to read and understand English
  • Provide written informed consent (subjects 12- 17 years of age provide written as sent and/ or parent or legal guardian provide written consent)
  • Purchase the investigational product

Exclusion Criteria

  • Have participated in a study involving OTC analgesics in the last 12 months
  • They or someone else in the household work for a market research company, an advertising agency, a public relations firm, pharmaceutical company, as a healthcare professional, or as part of a health care practice
  • Have a history of known allergies to nonsteroidal anti-inflammatory drugs (NSAIDs) (i.e., Naproxen, Ibuprofen, etc) or Aspirin
  • Have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days
  • (Female subjects) are pregnant or breastfeeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00751400). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search